| Dr Christine E Fuller, MD | |
|
3333 Burnet Ave, Ml 1035, Cincinnati, OH 45229-3026 | |
| (513) 636-4261 | |
| (513) 636-3924 |
| Full Name | Dr Christine E Fuller |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 29 Years |
| Location | 3333 Burnet Ave, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851394019 | NPI | - | NPPES |
| 3496626 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | 36654 (Tennessee) | Secondary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 35.127255 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospital S U N Y Health Science Center | Syracuse, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Pathologists Laboratories, Llp | 8325038276 | 23 |
News Archive
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Isis Pharmaceuticals, Inc. today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMN Rx and are continuing to receive treatment in an open-label extension (OLE) study.
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer.
"Most people focus on the dislike of the preparation, the need to arrange transportation and the fear of being anesthetized during the procedure and then potentially getting a cancer diagnosis," says Neil Gupta, MD, MPH, Director of Endoscopy at Loyola University Health System. "Screening colonoscopy is a very critical examination that really can determine life and death when it comes to colon cancer. It is now clear that not every colonoscopy is equal. Once you've decided it's time to get a screening colonoscopy, the next step is to make sure that you get a high-quality one."
Insmed Inc., a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2010.
› Verified 7 days ago
| Entity Name | University Pathologists Laboratories, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033150917 PECOS PAC ID: 8325038276 Enrollment ID: O20040513001074 |
News Archive
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Isis Pharmaceuticals, Inc. today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMN Rx and are continuing to receive treatment in an open-label extension (OLE) study.
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer.
"Most people focus on the dislike of the preparation, the need to arrange transportation and the fear of being anesthetized during the procedure and then potentially getting a cancer diagnosis," says Neil Gupta, MD, MPH, Director of Endoscopy at Loyola University Health System. "Screening colonoscopy is a very critical examination that really can determine life and death when it comes to colon cancer. It is now clear that not every colonoscopy is equal. Once you've decided it's time to get a screening colonoscopy, the next step is to make sure that you get a high-quality one."
Insmed Inc., a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2010.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christine E Fuller, MD 3333 Burnet Ave, Ml 1035, Cincinnati, OH 45229-3026 Ph: (513) 636-4261 | Dr Christine E Fuller, MD 3333 Burnet Ave, Ml 1035, Cincinnati, OH 45229-3026 Ph: (513) 636-4261 |
News Archive
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Isis Pharmaceuticals, Inc. today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMN Rx and are continuing to receive treatment in an open-label extension (OLE) study.
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer.
"Most people focus on the dislike of the preparation, the need to arrange transportation and the fear of being anesthetized during the procedure and then potentially getting a cancer diagnosis," says Neil Gupta, MD, MPH, Director of Endoscopy at Loyola University Health System. "Screening colonoscopy is a very critical examination that really can determine life and death when it comes to colon cancer. It is now clear that not every colonoscopy is equal. Once you've decided it's time to get a screening colonoscopy, the next step is to make sure that you get a high-quality one."
Insmed Inc., a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2010.
› Verified 7 days ago
Bruce G Storrs, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 375 Dixmyth Ave, Cincinnati, OH 45220 Phone: 513-872-1400 | |
Mei Liang, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Lab Medicine Building, Cincinnati, OH 45219 Phone: 513-584-3834 Fax: 513-558-2289 | |
Parsa Hodjat, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 3333 Burnet Ave., Ml 1035, Cincinnati, OH 45229 Phone: 513-636-4261 Fax: 513-636-3924 | |
Gregory Retzinger, MD Pathology Medicare: Medicare Enrolled Practice Location: 231 Albert Sabin Way, Department Of Pathology, Cincinnati, OH 45267 Phone: 513-558-4500 Fax: 513-558-2289 | |
Ila N Mehta Iii, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 375 Dixmyth Ave, Cincinnati, OH 45220 Phone: 513-624-4337 | |
Jiang Wang, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-584-1000 Fax: 513-584-3778 | |
Dani S Zander, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-584-7284 Fax: 513-584-3807 |